Noubar Afeyan, Flagship CEO (Victor Boyko/Getty Images for Aurora Humanitarian Initiative)
March 30, 2021 07:01 AM EDTUpdated March 31, 07:12 AM
Financing

Flag­ship start­up Omega takes lead 'epige­nom­ic con­troller' can­di­date clos­er to the clin­ic with new $126M round

Kyle Blankenship

In its quest to drug the un­drug­gable, Flag­ship Pi­o­neer­ing start­up Omega Ther­a­peu­tics is chas­ing a moon­shot with “epige­nom­ic con­trollers” to get all of the ben­e­fits …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

Ex­clu­sive: Bain-backed mus­cu­loskele­tal biotech rais­es $120M for trio of clin­i­cal-stage bi­o­log­ics

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times